New data announced from Phase IIIb TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis – Incyte
Incyte announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had… read more.

